IRADIMED CORPORATION to Hold Third Quarter of 2025 Financial Results Conference Call on November 3, 2025
IRADIMED CORPORATION (NASDAQ: IRMD) will release its Q3 2025 financial results before the market opens on Monday, November 3, 2025. Management will host a conference call the same day at 11:00 a.m. Eastern Time to discuss results and answer questions.
Interested participants must register to receive a dial-in number and unique PIN via the provided registration link. A real-time webcast will be available at the company investor events page and a recording will be posted on the company website after the call.
IRADIMED CORPORATION (NASDAQ: IRMD) rilascerà i suoi risultati finanziari del Q3 2025 prima dell'apertura del mercato lunedì 3 novembre 2025. La direzione terrà una conference call lo stesso giorno alle 11:00 a.m. Eastern Time per discutere i risultati e rispondere alle domande.
Gli interessati devono registrarsi per ricevere un numero di accesso e un PIN unici tramite il link di registrazione fornito. Una webcast in tempo reale sarà disponibile sulla pagina eventi per gli investitori dell'azienda e una registrazione sarà pubblicata sul sito web dell'azienda dopo la chiamata.
IRADIMED CORPORATION (NASDAQ: IRMD) divulgará sus resultados financieros del tercer trimestre de 2025 antes de la apertura del mercado el lunes 3 de noviembre de 2025. La dirección organizará una conferencia telefónica el mismo día a 11:00 a.m. Eastern Time para discutir los resultados y responder preguntas.
Los participantes interesados deben registrarse para recibir un número de marcación y un PIN único a través del enlace de registro proporcionado. Habrá una webcast en tiempo real disponible en la página de eventos para inversores de la empresa y una grabación se publicará en el sitio web de la empresa después de la llamada.
IRADIMED CORPORATION (NASDAQ: IRMD)은 2025년 11월 3일 월요일 시장 개장 전에 2025년 3분기 재무 실적을 발표합니다. 경영진은 같은 날 동부 시간 기준 오전 11시에 컨퍼런스 콜을 주최하여 결과를 논의하고 질문에 답합니다.
관심 있는 참가자는 제공된 등록 링크를 통해 전화 접속 번호와 고유 PIN을 받도록 등록해야 합니다. 회사의 투자자 이벤트 페이지에서 실시간 생중계가 가능하며 통화 후 회사 웹사이트에 녹음본이 게시됩니다.
IRADIMED CORPORATION (NASDAQ: IRMD) publiera ses résultats financiers du T3 2025 avant l'ouverture du marché le lundi 3 novembre 2025. La direction animera une conférence téléphonique le même jour à 11:00 a.m. Eastern Time pour discuter des résultats et répondre aux questions.
Les participants intéressés doivent s'inscrire pour recevoir un numéro d'appel et un PIN unique via le lien d'inscription fourni. Une webcast en direct sera disponible sur la page des événements investisseurs de l'entreprise et un enregistrement sera publié sur le site Web de l'entreprise après l'appel.
IRADIMED CORPORATION (NASDAQ: IRMD) wird seine Ergebnisse für das dritte Quartal 2025 vor Markteröffnung am Montag, den 3. November 2025, bekannt geben. Die Geschäftsführung wird am selben Tag um 11:00 a.m. Eastern Time eine Konferenzschaltung abhalten, um die Ergebnisse zu besprechen und Fragen zu beantworten.
Interessierte Teilnehmer müssen sich registrieren, um eine Durchwahl-Nummer und eine einzigartige PIN über den bereitgestellten Registrierungslink zu erhalten. Ein Echtzeit-Webcast wird auf der Investor-Events-Seite des Unternehmens verfügbar sein, und eine Aufzeichnung wird nach dem Anruf auf der Unternehmenswebsite veröffentlicht.
ستصدر شركة IRADIMED CORPORATION (المُدرجة في ناسداك: IRMD) نتائجها المالية للربع الثالث من عام 2025 قبل فتح السوق يوم الإثنين 3 نوفمبر 2025. ستعقد الإدارة مؤتمرًا هاتفيًا في نفس اليوم عند الساعة 11:00 صباحًا بتوقيت شرق الولايات المتحدة لمناقشة النتائج والإجابة على الأسئلة.
يجب على المشاركين المهتمين التسجيل للحصول على رقم اتصال ورمز PIN فريد عبر رابط التسجيل المقدم. ستتوفر بث مباشر عبر الإنترنت في صفحة فعاليات المستثمرين بالشركة وسيتم نشر تسجيل المكالمة على موقع الشركة الإلكتروني بعد الاتصال.
IRADIMED CORPORATION (NASDAQ: IRMD) 将于 2025 年 11 月 3 日星期一市场开盘前公布其 2025 年第三季度财务业绩。管理层将于同日 美东时间 11:00 举行电话会议，讨论业绩并回答问题。
感兴趣的参与者必须通过提供的注册链接注册，以获取拨入号码和唯一的 PIN。公司投资者活动页面将提供实时网络广播，电话会议结束后，相关录音将发布在公司网站上。
- None.
- None.
ORLANDO, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 third quarter financial results before the market opens on Monday, November 3, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BIb4c35afb95154b348a034716bd7b99d8. Once registered, a dial-in number, unique pin, and instructions will be provided to participants.
The conference call will also be available real-time via the internet at http://www.iradimed.com/en-us/investors/events/. A recording of the call will be available on the Company’s website following the completion of the call.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging (“MRI”) compatible medical devices. We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system that is specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design allowing it to travel with the patient from their critical care unit, to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include: wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and; optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.
Please visit www.iradimed.com for more information.
Media Contact:
John Glenn
Chief Financial Officer
IRADIMED CORPORATION
(407) 677-8022
InvestorRelations@iradimed.com
FAQ
When will IRMD release Q3 2025 results and hold the conference call?
How do I register to join the IRADIMED (IRMD) Q3 2025 conference call?
Where can I listen to the IRMD Q3 2025 earnings call webcast?
Will a replay of the IRADIMED Q3 2025 conference call be available after the event?
What will IRADIMED management discuss on the November 3, 2025 call?
